8.27
-0.04 (-0.48%)
| Penutupan Terdahulu | 8.31 |
| Buka | 8.33 |
| Jumlah Dagangan | 952,143 |
| Purata Dagangan (3B) | 8,749,742 |
| Modal Pasaran | 2,835,198,464 |
| Harga / Jualan (P/S) | 106.33 |
| Harga / Buku (P/B) | 8.81 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,913.23% |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.72% |
| Nisbah Semasa (MRQ) | 9.01 |
| Aliran Tunai Operasi (OCF TTM) | -157.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.76 M |
| Pulangan Atas Aset (ROA TTM) | -23.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Nuvation Bio Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.20 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.14% |
| % Dimiliki oleh Institusi | 62.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2025 | 25,954,439 |
| Laurion Capital Management Lp | 30 Sep 2025 | 9,705,532 |
| Omega Fund Management, Llc | 30 Sep 2025 | 8,831,089 |
| Tang Capital Management Llc | 30 Sep 2025 | 4,200,000 |
| Abrams Capital Management, L.P. | 30 Sep 2025 | 3,811,513 |
| Redmile Group, Llc | 30 Sep 2025 | 3,031,009 |
| Aisling Capital Management Lp | 30 Sep 2025 | 2,960,659 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 12.00 (B. Riley Securities, 45.11%) | Beli |
| Median | 10.00 (20.92%) | |
| Rendah | 6.00 (Wedbush, -27.45%) | Beli |
| Purata | 9.57 (15.72%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 5.95 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Dec 2025 | 10.00 (20.92%) | Beli | 7.88 |
| 19 Sep 2025 | 10.00 (20.92%) | Beli | 3.22 | |
| Truist Securities | 24 Nov 2025 | 11.00 (33.01%) | Beli | 7.41 |
| Citizens | 20 Nov 2025 | 10.00 (20.92%) | Beli | 7.01 |
| 04 Nov 2025 | 8.00 (-3.26%) | Beli | 4.83 | |
| B. Riley Securities | 19 Nov 2025 | 12.00 (45.10%) | Beli | 7.15 |
| RBC Capital | 04 Nov 2025 | 8.00 (-3.26%) | Beli | 4.83 |
| Wedbush | 13 Oct 2025 | 6.00 (-27.45%) | Beli | 3.68 |
| 08 Sep 2025 | 6.00 (-27.45%) | Beli | 3.49 | |
| Jefferies | 30 Sep 2025 | 10.00 (20.92%) | Beli | 3.70 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LIU DONGFANG | - | 7.95 | -20,000 | -158,900 |
| Jumlah Keseluruhan Kuantiti Bersih | -20,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -158,900 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 7.95 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LIU DONGFANG | Pegawai | 26 Nov 2025 | Jual (-) | 10,000 | 8.01 | 80,100 |
| LIU DONGFANG | Pegawai | 26 Nov 2025 | Pelaksanaan pilihan | 10,000 | - | - |
| LIU DONGFANG | Pegawai | 25 Nov 2025 | Jual (-) | 10,000 | 7.88 | 78,800 |
| LIU DONGFANG | Pegawai | 25 Nov 2025 | Pelaksanaan pilihan | 10,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |